Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q4 | Jan 21, 2026 | Meridian Small Cap Growth Fund | 0.9% | 0.0% | ALKT, AMPL, AXGN, CCSI, CDNA, CERT, GPCR, KEX, RELY, TPB, VCYT, VNOM, ZNAS | Biotechnology, growth, healthcare, Quality, small caps, technology, value | Healthcare was the portfolio's largest allocation and top-performing sector for the quarter. The manager continues to view the sector as undervalued relative to long-term fundamentals, noting it has lagged the broader market over the last four years. Multiple biotech holdings contributed positively, including Structure Therapeutics with promising obesity therapy trials, Axogen with peripheral nerve regeneration technology, and Zenas BioPharma with autoimmune disease treatments in Phase 3 trials. The fund emphasizes investing in high-quality businesses with recurring revenue, sustainable competitive advantages, strong balance sheets, and clear visibility into sustainable earnings growth. This quality bias created a modest headwind during the quarter as lower-quality stocks outperformed. | ZBIO AXGN GPCR RELY CERT CCSI EXAS TNDM GMED RELY DOCS CERT |
View |
| 2023 Q4 | Jan 27, 2024 | Baron Opportunity Fund | 4.0% | 25.1% | AMZN, ARGX, GPCR, ILMN, LRCX, MSFT, NVDA, TTD | - | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Seeking Alpha | Seeking Alpha | Structure Therapeutics Inc. | Pharmaceuticals | Biotechnology | Bull | NASDAQ Stock Market | aleniglipron, biotechnology, competitive landscape, Genentech deal, GLP-1 receptor agonists, investment strategy, market cap, oral weight-loss drugs, pharmaceutical industry, Phase III trials | View Pitch |
| Jan 24, 2026 | Fund Letters | Chad Meade | Structure Therapeutics, Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, Clinicaltrials, Glp1, Obesity, Oraltherapy | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| Eli Casdin | Casdin Capital | $1.6B | $81.7M | 5.08% | 1,175,000 | -380,000 | -24.44% | 1.6665% |
| Peter Chernin | TCG Crossover | $3.0B | $64.0M | 2.12% | 920,857 | -142,143 | -13.37% | 1.3060% |
| Neil Kumar | Ikarian Capital | $1.2B | $335,510 | 0.03% | 4,824 | -158,413 | -97.04% | 0.0068% |
| Oleg Nodelman | EcoR1 Capital | $2.2B | $23.3M | 1.06% | 334,380 | +334,380 | +100.00% | 0.4742% |
| Paul Tudor Jones | Tudor Investment Corp | $53.4B | $2.4M | 0.00% | 35,053 | +35,053 | +100.00% | 0.0497% |
| Mark Bussard | Rock Springs Capital | $1.9B | $52.0M | 2.68% | 748,236 | -202,918 | -21.33% | 1.0612% |
| Dmitry Balyasny | Balyasny Asset Management | $76.6B | $15.0M | 0.02% | 216,199 | -245,354 | -53.16% | 0.3066% |
| Israel Englander | Millennium Management LLC | $233.2B | $10.6M | 0.00% | 152,560 | -1,121,991 | -88.03% | 0.2164% |
| David Siegel & John Overdeck | Two Sigma Investments | $67.5B | $6.6M | 0.01% | 95,543 | -87,368 | -47.77% | 0.1355% |
| James E. Flynn | Deerfield Management | $6.9B | $53.4M | 0.78% | 767,993 | +394,586 | +105.67% | 1.0892% |
| Roderick Wong | RTW Investments | $10.0B | $7.0M | 0.07% | 100,000 | +100,000 | +100.00% | 0.1418% |
| Tom Steyer | Farallon Capital Management | $21.2B | $31.6M | 0.15% | 454,000 | +454,000 | +100.00% | 0.6439% |
| Rich Handler | Jefferies | $19.3B | $7.2M | 0.04% | 102,993 | -67,352 | -39.54% | 0.1461% |